Chul Woo Ahn

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.7K citations · Full text

Diabetes Management, Cardiovascular Disease, Diabetes +6

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Metabolic Significance of Nonalcoholic Fatty Liver Disease in Nonobese, Nondiabetic Adults

Hae Jin Kim, Hyeong Jin Kim, Kwang Eun Lee et al. · Archives of Internal Medicine · 2004 · 432 citations · Full text

Elevated TyG Index Predicts Progression of Coronary Artery Calcification

Kahui Park, Chul Woo Ahn, Sang Bae Lee et al. · Diabetes Care · 2019 · 413 citations · Full text